Completing a special protocol assessment process with the FDA, Alexion Pharmaceuticals Inc. plans to begin a Phase III program of eculizumab for the chronic orphan blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). (BioWorld Today)

While DAC:GLP-1 hit its primary endpoint as a diabetes monotherapy in a Phase II trial that evaluated it in four doses, the drug's nausea and vomiting side effects sent ConjuChem's stock tumbling. (BioWorld Today)